– USA, CA – Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the appointment of Vicki Vakiener to its Board as an independent director, effective May 2, 2022.
“Vicki is a senior executive with an impressive track record of leading organizations to successfully commercialize important medicines.” said Board Chairman, Dr. Douglass Given.
About Victoria Vakiener
Vicki Vakiener currently serves on the board of directors of Chimerix, a clinical-stage biopharmaceutical company. From November 2018 through September 2021, she served as CCO of Epizyme, Inc. where she built the commercial organization and launched TAZVERIK for two indications within six months. Before joining Epizyme, Ms. Vakiener was an executive at Johnson & Johnson for more than twenty years where she held positions of leadership with increasing responsibility across the company’s pharmaceutical and diagnostics businesses. Ms. Vakiener began her pharmaceutical career at Schering-Plough, where she spent nine years in both scientific and commercial roles.
“I’ve watched Arrowhead aggressively grow its pipeline and expand the reach of its RNAi technology over the years,” said Vicki Vakiener. “I am excited to join the Board now to help contribute to its next phase of growth as Arrowhead takes the necessary steps to become an emerging commercial-stage company.”
Ms. Vakiener received a B.S. in Biochemistry from Albright College.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information: https://arrowheadpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
